Madhu Kumar analyst GOLDMAN SACHS

Currently out of the existing stock ratings of Madhu Kumar, 147 are a BUY (64.19%), 63 are a HOLD (27.51%), 19 are a SELL (8.3%).

Madhu Kumar

Work Performance Price Targets & Ratings Chart

Analyst Madhu Kumar works at GOLDMAN SACHS with a stock forecast success ratio of 56.39% fulfilled within 159.54 days on average. Previously, Madhu Kumar worked at BAIRD.

Madhu Kumar’s has documented 446 price targets and ratings displayed on 47 stocks. The coverage is on Healthcare, Consumer Defensive sectors.

Most recent stock forecast was given on DVAX, Dynavax Technologies at 01-Feb-2024.

Wall Street Analyst Madhu Kumar

Analyst best performing recommendations are on ARCT (ARCTURUS THERAPEUTICS HOLDINGS).
The best stock recommendation documented was for ARCT (ARCTURUS THERAPEUTICS HOLDINGS) at 12/29/2020. The price target of $69 was fulfilled within 10 days with a profit of $26.64 (62.89%) receiving and performance score of 62.89.

Average potential price target upside

ABUS Arbutus Biopharma Corp ALNY Alnylam Pharmaceuticals APLS Apellis Pharmaceuticals ARCT Arcturus Therapeutics Holdings ARWR Arrowhead Pharmaceuticals CLVS Clovis Oncology DRNA Dicerna Pharmaceuticals EDIT Editas Medicine IOVA Iovance Biotherapeutics MGTA Magenta Therapeutics NTLA Intellia Therapeutics RGLS Regulus Therapeutics SNDX Syndax Pharmaceuticals APRE Aprea Therapeutics CLLS Cellectis SA KRYS Krystal Biotech PASG Passage Bio GRTS Gritstone Oncology VIR Vir Biotechnology ACHN Achillion Pharmaceuticals ALEC Alector ARVN Arvinas AVEO AVEO Pharmaceuticals CERE Cerevel Therapeutics Holdings DVAX Dynavax Technologies EWTX Edgewise Therapeutics FIXX Homology Medicines MGEN Viridian Therapeutics RETA Reata Pharmaceuticals APLT Applied Therapeutics HZNP Horizon Pharma PLC JAZZ Jazz Pharmaceuticals PLC SBPH Spring Bank Pharmaceuticals TCDA Tricida CYTK Cytokinetics FULC Fulcrum Therapeutics ALNA Allena Pharmaceuticals ASMB Assembly Biosciences BOLD Audentes Therapeutics EIGR Eiger Biopharmaceuticals MDCO The Medicines Company ONCE Spark Therapeutics QURE Uniqure NV TTPH Tetraphase Pharmaceuticals INFA Informatica MYOV Myovant Sciences Ltd UTZ Utz Brands

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

4

$0.71 (21.58%)

4

23 days ago

1/9 (11.11%)

$1.29 (47.60%)

139

Buy

4

$0.71 (21.58%)

4

1 months 22 days ago

0/5 (0%)

$1 (33.33%)

Buy

5

$1.71 (51.98%)

6

2 months 25 days ago

0/13 (0%)

$2.21 (79.21%)

Buy

5

$2.08 (71.23%)

2 years 3 months 24 days ago

0/1 (0%)

$2.11 (73.01%)

Buy

7

2 years 10 months 28 days ago

0/4 (0%)

$3.7 (112.12%)

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

Which stock is Madhu Kumar is most bullish on?

Potential upside of $21.99 has been obtained for ARVN (ARVINAS)

Which stock is Madhu Kumar is most reserved on?

Potential downside of -$3.9 has been obtained for INFA (INFORMATICA)

What Year was the first public recommendation made by Madhu Kumar?

On 2016

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?